Mitochondria are dynamic organelles, crucial for metabolic homeostasis and energy balance. Their integrity and functionality depend on a finely tuned network of proteins that maintain their structural architecture and regulate metabolic responses to environmental stimuli. The newly identified microprotein SLC35A4-MP was first characterized in 2024 when researchers decoded its genetic sequence hidden within an upstream open reading frame (uORF) of messenger RNA (mRNA). Contrary to the traditional understanding that each mRNA codes for a single protein, these uORFs were previously dismissed as noncoding segments. However, advances in ribosome profiling and proteogenomic techniques have revealed that such regions can indeed encode small yet functionally indispensable microproteins.

The Salk Institute team focused on the functional validation of SLC35A4-MP in vivo, employing sophisticated genetic knockout models in mice. By eliminating the gene encoding SLC35A4-MP specifically in brown adipose tissue—a metabolically highly active fat depot responsible for thermogenesis—the researchers probed the physiological impact of this microprotein. Their findings exposed a profound disruption in mitochondrial morphology and function, accompanied by impaired adaptive thermogenesis during cold stress and suboptimal lipid metabolism under dietary challenges.

Microscopic examination of brown fat cells lacking SLC35A4-MP revealed mitochondria exhibiting abnormal enlargement, structural disorganization, and signs of inflammation. These organelles appeared swollen, with compromised cristae—the internal folds integral for efficient oxidative phosphorylation. Such morphological alterations were accompanied by a cascade of cellular remodeling events, indicative of metabolic distress and inflammation. This cellular milieu mirrors pathological conditions often observed in obesity and age-related metabolic disorders, suggesting that the loss of this microprotein mirrors disease-like metabolic dysfunction in vivo.

On the molecular level, the absence of SLC35A4-MP disrupted key pathways involved in mitochondrial bioenergetics and lipid handling. Brown adipocytes without this microprotein could not effectively ramp up energy expenditure in response to cold exposure, a hallmark of healthy mitochondrial adaptation. This failure highlights the critical regulatory role of SLC35A4-MP in facilitating metabolic flexibility through maintaining mitochondrial integrity. The data suggest that SLC35A4-MP may interact with structural components of the mitochondrial membrane or signaling proteins that govern mitochondrial dynamics, thereby preserving organelle function during metabolic stress.

This study overturns prior dismissals of microproteins as mere genetic noise, placing them firmly as central players in cellular physiology. The discovery of SLC35A4-MP’s function extends beyond brown fat biology; mitochondria are omnipresent in all cell types, rendering this microprotein a likely candidate for broader systemic influence. Consequently, SLC35A4-MP and similar microproteins represent a largely untapped reservoir of potential targets for treating metabolic diseases where mitochondrial dysfunction is a driving force, such as type 2 diabetes, obesity, and age-associated decline.

Technical advances in genomics and proteomics have propelled the identification of microproteins encoded within previously overlooked open reading frames. These tiny proteins, often fewer than 100 amino acids, are now recognized as critical modulators of diverse biological processes. The work at the Salk Institute exemplifies the scientific shift from gross annotation errors to appreciating the sophistication hidden in the genome’s so-called “dark matter”. The study employed rigorous biochemical assays combined with in vivo physiological testing, establishing a direct causal link between microprotein expression and mitochondrial health.

The functional exploration of SLC35A4-MP in the context of metabolic stress conditions—such as cold exposure and high-fat diet—provides a valuable model for understanding how cells maintain energy homeostasis. Brown adipose tissue acts as a metabolic furnace that dissipates excess calories as heat, largely mediated by mitochondrial uncoupling. Disruption of its function through loss of SLC35A4-MP portrays a compelling scenario where microprotein loss leads to a cascade of bioenergetic failure, cellular inflammation, and systemic metabolic impairments.

Importantly, this research brings to the forefront the notion that many human diseases may involve previously uncharacterized microproteins. Their small size has traditionally made them elusive to conventional proteomic approaches, underscoring the necessity of innovative methodologies to decode their presence and role. As more microproteins are cataloged and functionally validated, biomedical science stands at the threshold of revealing a new layer of molecular medicine that could redefine diagnostics and therapeutics for a variety of conditions.

The excitement surrounding this discovery is palpable within the scientific community, as it challenges the one-gene-one-protein paradigm and expands our understanding of genome complexity. The researchers at Salk express optimism that their findings will catalyze further studies into the microproteome, illuminating the diverse physiological relevance of these small proteins. Their hope is that such knowledge will ultimately translate into novel treatments aimed at bolstering mitochondrial function and combating metabolic and age-related diseases.

In conclusion, the identification and characterization of SLC35A4-MP as a critical regulator of mitochondrial structure and adaptive metabolism in brown fat herald a paradigm shift in mitochondrial biology. This breakthrough underscores the profound impact of microproteins, previously obscured within the genome’s “dark” sequences, in governing essential cellular processes. As research continues to unravel the complexities of these miniature proteins, the landscape of molecular biology and metabolic disease treatment is poised for revolutionary advances.

Subject of Research:
Microprotein SLC35A4-MP’s role in mitochondrial structure and metabolic regulation within brown adipose tissue of mice.

Article Title:
Abnormal mitochondrial structure and function in brown adipose tissue of SLC35A4-MP knockout mice

News Publication Date:
29-Aug-2025

Web References:
https://www.science.org/doi/10.1126/sciadv.ads7381
https://www.salk.edu/news-release/new-ai-tool-illuminates-dark-side-of-the-human-genome/
https://www.salk.edu/news-release/finding-microproteins-to-treat-obesity-and-metabolic-disorders/

References:
Rocha, A., Pinto, A., Diedrich, J., Shan, H., Vieira de Souza, E., Vaughan, J., Foster, M., Schmedt, C., Perksin, G., Ellisman, M., Plucińska, K., Cohen, P., Sampath, S., & Saghatelian, A. (2025). Abnormal mitochondrial structure and function in brown adipose tissue of SLC35A4-MP knockout mice. Science Advances. https://doi.org/10.1126/sciadv.ads7381

Image Credits:
Salk Institute

Lipid nanoparticles serve as protective carriers for RNA molecules, shielding them from degradation within the bloodstream and facilitating their entry into target cells. Despite their critical role, optimizing LNP formulations has long been an arduous process given the complex interplay of lipid components that compose these particles. Conventional methods, reliant on combinatorial testing of various lipid mixtures, are both time-consuming and costly. To overcome this bottleneck, the MIT team developed a computational framework named COMET, a transformer-based neural network model that learns the intricate relationships among nanoparticle ingredients and predicts optimal compositions without the need for exhaustive empirical screening.

COMET’s design draws inspiration from the same artificial intelligence models that underlie sophisticated language processing systems such as ChatGPT. Rather than parsing words and grammar, COMET interprets how distinct chemical building blocks behave and interact within lipid nanoparticles. The transformers architecture endows the model with the ability to capture complex dependencies and non-linear interactions between multiple chemical components simultaneously, a task which traditional AI methods typically struggle with when applied to multi-component systems like LNPs.

To fuel this advanced learning capability, the researchers painstakingly compiled a rich dataset comprising approximately 3,000 unique lipid nanoparticle formulations. Each formulation varied systematically in its composition of four primary components: cholesterol, a helper lipid, an ionizable lipid, and polyethylene glycol (PEG)-conjugated lipid. The team evaluated the functional efficacy of each particle by measuring its ability to deliver messenger RNA (mRNA) encoding fluorescent proteins to cultured mouse skin cells. This extensive dataset provided the foundational knowledge necessary for COMET to discern the subtle yet critical influences of each component on nanoparticle performance.

Following the rigorous training phase, COMET demonstrated remarkable proficiency in forecasting novel LNP mixtures predicted to outperform those present in the initial dataset. Validation experiments confirmed that these AI-suggested nanoparticles delivered mRNA with greater efficiency, occasionally surpassing commercial formulations in potency. This success signifies a monumental leap forward in the rational design of nanoparticle-based delivery systems, heralding a new era of precision-engineered therapeutics.

The implications extend well beyond vaccine development alone. The MIT research team has leveraged this predictive platform to explore the inclusion of a fifth component—branched poly beta amino esters (PBAEs), a class of polymers known for their innate nucleic acid delivery capabilities. By integrating PBAEs into nanoparticle formulations, COMET was retrained with a supplementary dataset of approximately 300 LNPs containing this polymeric component. With this enriched modeling, the researchers could predict complex formulations that harness the synergistic effects of lipids and polymers to augment delivery efficiency further.

Moreover, the researchers customized their strategy to accommodate cellular specificity, a critical factor for targeted therapies. Harnessing COMET’s flexibility, they trained the model to predict LNP efficiency in delivering mRNA to distinct cell types. Using Caco-2 cells, derived from human colorectal adenocarcinoma and commonly employed as a model of the intestinal epithelium, they confirmed that the algorithm could effectively tailor nanoparticle formulations optimized for diverse biological environments. This adaptability opens doors to a wide array of therapeutic applications beyond systemic delivery, including oral vaccines and localized treatments.

Another pivotal advancement involved addressing the stability of lipid nanoparticles under lyophilization, or freeze-drying—a process commonly used to enhance the shelf life and ease of storage of pharmaceutical products. The durability of LNPs after lyophilization remains a significant challenge, frequently compromising their functional integrity. By incorporating freeze-drying performance into their training objectives, the MIT team used COMET to identify formulations that maintain nanoparticle efficacy post-lyophilization, simplifying logistics for distribution and global deployment of RNA therapies.

Giovanni Traverso, the principal investigator of the study and an associate professor at MIT, emphasized the transformative potential of this AI-driven design approach. By accelerating the identification of optimal nanoparticle formulations tailored to specific cells, delivery modes, and storage conditions, the platform promises not just speed but adaptability. This versatility is critical for rapid response to emerging pathogens and for personalization in metabolic disease treatment, including obesity and diabetes, fields targeted by ARPA-H-funded research projects.

The ongoing expansion of this platform seeks to integrate the prediction model with novel therapeutic payloads, such as GLP-1 mimetics—compounds that imitate the hormone glucagon-like peptide-1 and possess potent anti-diabetic and weight-loss properties. The coupling of optimized LNP carriers with such therapeutics could mark a paradigm shift in managing chronic diseases, transforming patient experiences by enabling oral RNA delivery methods that previously were unfeasible.

This research, formally published in the prestigious journal Nature Nanotechnology, reflects the fruitful intersection of molecular biology, materials science, and artificial intelligence. It exemplifies how transformer-based neural networks, primarily known for language understanding, can be ingeniously repurposed to unravel complex biochemical design spaces. The success of the COMET model underscores the vast potential of AI in overcoming long-standing barriers in drug delivery and precision medicine.

The advancement offers a glimpse into a future where the design of pharmaceutical nanoparticles can be algorithmically optimized to meet diverse clinical needs rapidly. RMIST-funded by institutions including the Koch Institute’s GO Nano Marble Center, the MIT Department of Mechanical Engineering, and healthcare partners such as Brigham and Women’s Hospital, this multidisciplinary work exemplifies collaborative innovation spanning computational and experimental domains.

As RNA-based therapeutics continue to expand their impact—from vaccines that thwart pandemics to gene therapies that treat metabolic diseases—the adoption of AI-driven design platforms like COMET will be crucial. This technology not only trims research timelines but elevates the quality and targeting of RNA delivery systems, making personalized medicine more accessible and impactful.

Subject of Research: Design and optimization of lipid nanoparticles for RNA delivery using artificial intelligence

Article Title: ‘Designing lipid nanoparticles using a transformer-based neural network’

News Publication Date: 15-Aug-2025

Web References: https://news.mit.edu/2024/mit-led-team-receives-funding-new-treatments-metabolic-disease-0205

References: Nature Nanotechnology (15-Aug-2025)

Keywords: Artificial intelligence, RNA, vaccine research, vaccine development, drug delivery, pharmaceuticals

Lentiviral vectors are a category of viral vectors derived from lentiviruses, a subclass of retroviruses capable of integrating their genetic material stably into the host genome. These vectors are highly valued in gene therapy due to their ability to transduce non-dividing cells and mediate long-lasting gene expression. However, delivering these vectors efficiently and selectively to hepatocytes in vivo has long posed a formidable challenge. Traditional approaches often suffer from low transduction efficiency, off-target effects, and immunogenicity, limiting their clinical potential.

The team’s innovative enhancement revolves around optimizing both the lentiviral vector design and in vivo delivery protocols to circumvent these limitations. By systematically modifying the viral envelope proteins and refining vector dosing and administration routes, the researchers achieved unprecedented transduction efficiencies in hepatocytes while minimizing off-target transduction of other cell types. This stereochemical and tropism optimization is central to the vector’s success, as it improves selective binding and uptake by hepatocytes situated within the complex architecture of the liver sinusoidal environment.

One core advancement described involves engineering the viral envelope glycoproteins to boost their affinity for receptors uniquely expressed on hepatocytes. Leveraging recent insights into liver receptor biology, such as the asialoglycoprotein receptor (ASGPR) and other membrane markers, the team tailored the surface proteins of lentiviral particles to promote receptor-mediated endocytosis specifically in hepatocytes. This selective vector-cell interaction significantly enhances internalization rates and subsequent integration of the therapeutic transgene.

Immunogenicity remains a critical hurdle in viral vector-based therapies, often triggering innate and adaptive immune responses that limit therapeutic windows and lead to vector clearance. Addressing this, the study details how the researchers incorporated stealth features within the vector capsules and employed transient immunosuppressive regimens, dampening immune recognition without compromising host defenses. These strategies were both innovative and biocompatible, minimizing inflammation and extending vector persistence in the liver tissue.

Another remarkable achievement is the improved tropism balancing, where vector design prioritizes hepatocyte transduction while simultaneously reducing unintended uptake by liver-resident immune cells such as Kupffer cells and hepatic stellate cells. This specificity is vital because off-target transduction can lead to adverse responses and dilute the therapeutic effect. Detailed in vivo studies conducted in animal models demonstrated that the optimized vectors retained long-term expression of the transgene exclusively within hepatocytes, with negligible gene transfer to non-parenchymal liver cells or systemic tissues.

From a mechanistic standpoint, the researchers also explored the intracellular trafficking pathways post vector entry into hepatocytes. They identified molecular chaperones and endosomal sorting complexes that facilitate the nuclear entry of the lentiviral pre-integration complex, thus ensuring efficient genome integration. By manipulating these intracellular pathways pharmacologically and genetically, they further enhanced transduction efficiency, adding another layer of control and optimization to the gene delivery system.

Notably, the therapeutic payloads delivered by these lentiviral vectors encompass gene sequences designed to correct mutations responsible for inherited metabolic liver diseases such as ornithine transcarbamylase deficiency and familial hypercholesterolemia. The study includes preliminary proof-of-concept data showing partial to complete restoration of enzyme function following a single administration, underscoring the clinical promise of this approach as a durable, one-time treatment modality.

Importantly, the researchers also addressed concerns regarding insertional mutagenesis, a potential risk wherein vector integration disrupts oncogenes or tumor suppressor genes. Through integration site analysis and genomic profiling, the study confirms a favorable integration pattern with minimal preference for proto-oncogenic regions. This safety profile is paramount for advancing lentiviral gene therapies toward regulatory approval and eventual clinical deployment.

Beyond the technical improvements in vector design, the study highlights innovative delivery strategies that maximize vector bioavailability in the liver. Employing optimized intravenous infusion protocols coupled with transient vascular modulation techniques, such as transient portal vein occlusion and vasodilators, the team enhanced vector perfusion and penetration into liver lobules. These physiological manipulations facilitate efficient vector distribution within the hepatic sinusoids, overcoming physical barriers that have historically diminished gene transfer efficacy.

The translational potential of this research resonates profoundly given the liver’s centrality in systemic metabolism and its accessibility as a target organ. Diseases caused by single-gene mutations in hepatocytes have long been challenging to treat effectively, and current therapeutic options often rely on lifelong administration of drugs or liver transplantation. The breakthrough presented by Canepari and colleagues marks a significant stride towards curative, gene-based interventions that could alleviate the need for invasive procedures and chronic pharmacotherapy.

Equally transformative is the scalability and adaptability of the optimized lentiviral platform. The vector design principles and delivery protocols are amenable to various transgene cassettes, enabling broader application across diverse genetic liver diseases. This flexibility also opens avenues for modifying immune tolerance mechanisms, metabolic reprogramming, and even liver regeneration strategies via engineered gene expression patterns.

As with all pioneering therapies, the path to human clinical trials requires rigorous evaluation of long-term efficacy and safety. The authors acknowledge ongoing studies to monitor vector persistence, immunological responses, and liver function over extended periods in large animal models. These efforts are crucial to establishing dose regimens and addressing potential adverse effects such as cumulative toxicity or unexpected insertional events.

To complement their molecular and physiological findings, the team employed cutting-edge imaging and single-cell sequencing technologies to visualize vector-cell interactions and transcriptomic changes post transduction. These methodologies provide unprecedented resolution into the dynamics of gene delivery and expression in situ, enabling precise fine-tuning of the therapeutic vectors and protocols.

In sum, the research led by Canepari, Milani, Simoni, and colleagues heralds a new era in in vivo lentiviral vector-mediated gene therapy for hepatocytes. Their meticulous integration of molecular engineering, immunological considerations, and physiological delivery innovations collectively pushes the boundaries of what is possible in genetic medicine. This seminal work not only broadens the toolkit for treating liver diseases but also sets foundational principles applicable to other organ systems reliant on targeted gene delivery.

As the gene therapy field rapidly evolves, advances such as these underscore the vital interplay between basic science, translational research, and clinical aspiration. The enhanced potency and specificity of lentiviral vectors now herald realistic prospects for curing debilitating liver diseases previously considered intractable. Future studies will undoubtedly build upon this platform, refining vector designs and delivery methods, and paving the way for new generations of precision gene therapeutics that could revolutionize medicine globally.

Subject of Research: Enhancing lentiviral vector-mediated gene therapy targeting hepatocytes in vivo.

Article Title: Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes.

Article References: Canepari, C., Milani, M., Simoni, C. et al. Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes. Nat Commun 16, 4802 (2025). https://doi.org/10.1038/s41467-025-60073-0

Image Credits: AI Generated